Sugi Predict

Sugi Predict / Compounds / SCHEMBL128343

SCHEMBL128343

SCHEMBL128343

Nc1cccnc1C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.61
▸ MAPT P10636 2/20 0.61
▸ L3MBTL1 Q9Y468 2/20 0.61
▸ ALDH1A1 P00352 2/20 0.61
▸ CYP3A4 P08684 1/20 0.61
▸ ALOX15 P16050 1/20 0.61
▸ TSHR P16473 1/20 0.61
▸ BLM P54132 1/20 0.61
▸ AGER Q15109 1/20 0.61
▸ NPSR1 Q6W5P4 1/20 0.61
▸ NAPRT Q6XQN6 3/20 0.53
▸ CYP1A2 P05177 1/20 0.53
▸ MYC P01106 1/20 0.49
▸ GRM4 Q14833 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ LMNA P02545 2/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ P4HTM Q9NXG6 1/20 0.43
▸ PIM1 P11309 1/20 0.43
▸ PIM3 Q86V86 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2280224 0.98 KDM4E (0.59) KDM4EMAPTL3MBTL1ALDH1A1CYP3A4
SCHEMBL29262306 0.98 KDM4E (0.59) KDM4EMAPTL3MBTL1ALDH1A1CYP3A4
Acetamide SCHEMBL27631466 0.92 KDM4E (0.53) KDM4EMAPTL3MBTL1ALDH1A1CYP3A4
SCHEMBL20558075 0.84 GRM4 (0.49) KDM4EMAPTL3MBTL1ALDH1A1CYP3A4
SCHEMBL27940918 0.83 KDM4E (0.52) KDM4EMAPTL3MBTL1ALDH1A1CYP3A4
SCHEMBL699068 0.83 MKNK1 (0.49) KDM4EMAPTL3MBTL1ALDH1A1CYP3A4
SCHEMBL29385675 0.83 MKNK1 (0.49) KDM4EMAPTL3MBTL1ALDH1A1CYP3A4
SCHEMBL28124169 0.83 GRM4 (0.47) KDM4EMAPTL3MBTL1ALDH1A1CYP3A4
SCHEMBL8694839 0.82 KDM4E (0.46) KDM4EMAPTL3MBTL1ALDH1A1CYP3A4
SCHEMBL3380838 0.81 GRM4 (0.46) KDM4EMAPTL3MBTL1ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4127157-B1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS ENCODIA INC (US) 2026-02-11 — — EP claimed
US-20260002063-A1 CMP POLISHING LIQUID, CMP POLISHING LIQUID SET, AND POLISHING METHOD RESONAC CORP (JP) 2026-01-01 — — US claimed
CN-120189920-A Aerogel composite purification material and preparation method and application thereof 中国烟草总公司郑州烟草研究院 2025-06-24 — — CN claimed
CN-120026327-A Acidic etching solution for aluminum-based circuit 深圳市溢诚电子科技有限公司 2025-05-23 — — CN claimed
CN-116640290-B Cement grinding aid with water reducing function and processing technology thereof 江苏仁爱建材科技开发有限公司 2025-01-14 — — CN claimed
CN-118812691-B Large-scale preparation method of conopeptide 杭州信海医药科技有限公司 2024-12-20 — — CN claimed
CN-119137710-A Polishing liquid for CMP, polishing liquid set for CMP and polishing method 株式会社力森诺科 2024-12-13 — — CN claimed
CN-118812691-A Large-scale preparation method of conopeptide 杭州信海医药科技有限公司 2024-10-22 — — CN claimed
WO-2024111174-A1 CMP POLISHING LIQUID, CMP POLISHING LIQUID SET, AND POLISHING METHOD 株式会社レゾナック 2024-05-30 — — WO claimed
CN-118063428-A Aminopicolinic acid compound containing 6-substituted pyrazole and preparation method and application thereof 中国农业大学 2024-05-24 — — CN claimed
EP-3088525-A1 ARTIFICIAL MATCH-TYPE MIRNA FOR CONTROLLING GENE EXPRESSION AND USE THEREFOR Bonac Corporation (JP) 2016-11-02 — — EP claimed
WO-2015134608-A1 COMPOSITIONS AND METHODS FOR ORAL DELIVERY OF ENCAPSULATED 3-AMINOPYRIDINE-2-CARBOXALDEHYDE PARTICLES NANOTHERAPEUTICS, INC. (US) 2015-09-11 — — WO claimed
US-20150073124-A1 micro-RNA INHIBITOR BONAC CORPORATION (JP) 2015-03-12 — — US claimed
EP-2824184-A1 micro-RNA INHIBITOR Bonac Corporation (JP) 2015-01-14 — — EP claimed
CN-104271742-A Micro RNA inhibitors BONAC CORP 2015-01-07 — — CN claimed
US-20110071165-A1 Aza- and polyazanthranyl amides and their use as medicaments NOVARTIS AG (CH) 2011-03-24 — — US claimed
US-7678818-B2 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. (US) 2010-03-16 — — US claimed
US-20060287339-A1 Aza- and polyazanthranyl amides and their use as medicaments SEIDELMANN DIETER 2006-12-21 — — US claimed
US-20040224968-A1 Aza-and polyazanthranyl amides and their use as medicaments NOVARTIS AG (CH) 2004-11-11 — — US claimed
EP-0562512-A1 Sulfonamido- and sulfonamidocarbonyl-pyridine-2-carboxamides and their pyridine-N-oxides, process for their preparation and their use as medicines HOECHST AKTIENGESELLSCHAFT (DE) 1993-09-29 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287339-A1 Aza- and polyazanthranyl amides and their use as medicaments VEGFA, AZI2, TPMT KDM4E 745/4885MAPT 1599/4885L3MBTL1 2584/4885
US-20040224968-A1 Aza-and polyazanthranyl amides and their use as medicaments AZI2, VEGFA, TPMT KDM4E 415/4885MAPT 1631/4885L3MBTL1 2780/4885
US-20150073124-A1 micro-RNA INHIBITOR AGO2, SLIRP, MSI2 KDM4E 1756/4885MAPT 2128/4885L3MBTL1 58/4885
US-20110071165-A1 Aza- and polyazanthranyl amides and their use as medicaments VEGFA, AZI2, TPMT KDM4E 745/4885MAPT 1599/4885L3MBTL1 2584/4885
US-20260002063-A1 CMP POLISHING LIQUID, CMP POLISHING LIQUID SET, AND POLISHING METHOD H1-0, H1-5, H1-2 KDM4E 585/4885MAPT 3576/4885L3MBTL1 2058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.